Close

Wedbush Starts Durata Therapeutics (DRTX) at Outperform; Safety, Potency, Convenience Underpin Positive Outlook of Dalbavancin

September 10, 2012 2:02 PM EDT Send to a Friend
Wedbush initiates coverage on Durata Therapeutics (NASDAQ: DRTX) with an Outperform. PT $20.00.

Analyst, Gregory R. Wade, said, "Durata’s ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login